Novo Nordisk A/S
NVO
$54.30
$0.020.04%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.69B | 11.02B | 12.25B | 10.51B | 9.82B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.69B | 11.02B | 12.25B | 10.51B | 9.82B |
| Cost of Revenue | 1.95B | 1.82B | 1.72B | 1.67B | 1.48B |
| Gross Profit | 9.74B | 9.20B | 10.52B | 8.84B | 8.34B |
| SG&A Expenses | 2.87B | 2.27B | 2.90B | 2.44B | 2.32B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3.50M | -1.97M | -105.76M | 14.88M | -58.44M |
| Total Operating Expenses | 6.60B | 5.54B | 6.16B | 5.52B | 5.26B |
| Operating Income | 5.09B | 5.47B | 6.08B | 4.98B | 4.56B |
| Income Before Tax | 5.14B | 5.22B | 5.08B | 5.07B | 3.66B |
| Income Tax Expenses | 1.11B | 1.13B | 1.05B | 1.04B | 762.14M |
| Earnings from Continuing Operations | 4.03B | 4.10B | 4.03B | 4.02B | 2.89B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.03B | 4.10B | 4.03B | 4.02B | 2.89B |
| EBIT | 5.09B | 5.47B | 6.08B | 4.98B | 4.56B |
| EBITDA | 5.73B | 6.01B | 6.33B | 5.30B | 4.86B |
| EPS Basic | 0.91 | 0.92 | 0.91 | 0.90 | 0.65 |
| Normalized Basic EPS | 0.72 | 0.74 | 0.83 | 0.71 | 0.63 |
| EPS Diluted | 0.91 | 0.92 | 0.91 | 0.90 | 0.65 |
| Normalized Diluted EPS | 0.72 | 0.73 | 0.83 | 0.71 | 0.63 |
| Average Basic Shares Outstanding | 4.44B | 4.44B | 4.45B | 4.45B | 4.46B |
| Average Diluted Shares Outstanding | 4.45B | 4.45B | 4.46B | 4.46B | 4.47B |
| Dividend Per Share | 0.57 | -- | 1.13 | 0.00 | 0.51 |
| Payout Ratio | -- | 121.49% | 0.00% | 57.08% | 0.00% |